Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $67

Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $67

Needham analyst Ami Fadia maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price target from $65 to $67.

byBenzinga Newsdesk

August 10, 2022

1 minute read

Needham analyst Ami Fadia maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price target from $65 to $67.

Will Apple Join The Party After Big Tech’s Earnings Outperformed Last Week? Here’s What One Analyst Says.

By Shanthi Rexaline

April 30, 10:30 AM

Big tech stalwarts Microsoft Corp. (NASDAQ:MSFT), Meta Platforms, Inc. (NASDAQ:META), Intel Corp. (NASDAQ:INTC) and Amazon, Inc. (NASDAQ:AMZN) reported…

AMZN

South African Gold Mining Stock AngloGold Ashanti Gets Upgraded, Gold Fields Downgraded

By Wayne Duggan

January 30, 1:37 PM

The SPDR Gold Trust (NYSE: GLD) is up 15.8% since Oct. 1, and gold prices are approaching $2,000 per ounce for the first time since April 2022.

News

Group One Trading Cuts Passive Stake In Silvergate Capital From 7.27% To 2.1% As Of Feb. 28

By Michael Horton

March 6, 6:16 PM

-SEC Filing

Wells Fargo Maintains Overweight on Walmart, Lowers Price Target to $130

By Benzinga Newsdesk

July 26, 6:54 AM

Wells Fargo analyst Edward Kelly maintains Walmart (NYSE:WMT) with a Overweight and lowers the price target from $150 to $130.

WMT

Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $67

Related Posts

Will Apple Join The Party After Big Tech’s Earnings Outperformed Last Week? Here’s What One Analyst Says.

South African Gold Mining Stock AngloGold Ashanti Gets Upgraded, Gold Fields Downgraded

Group One Trading Cuts Passive Stake In Silvergate Capital From 7.27% To 2.1% As Of Feb. 28

Wells Fargo Maintains Overweight on Walmart, Lowers Price Target to $130